This report contains market size and forecasts of Castrate Resistant Prostate Cancer Therapeutics in Global, including the following market information:
Global Castrate Resistant Prostate Cancer Therapeutics Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Castrate Resistant Prostate Cancer Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Chemotherapy Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Castrate Resistant Prostate Cancer Therapeutics include Sanofi, Johnson & Johnson, Bayer AG, Dendreon Pharmaceuticals LLC and Pfizer Inc, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Castrate Resistant Prostate Cancer Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Castrate Resistant Prostate Cancer Therapeutics Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Castrate Resistant Prostate Cancer Therapeutics Market Segment Percentages, by Type, 2022 (%)
Chemotherapy
Hormonal Therapy
Radiation Therapy
Other Treatment Types
Global Castrate Resistant Prostate Cancer Therapeutics Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Castrate Resistant Prostate Cancer Therapeutics Market Segment Percentages, by Application, 2022 (%)
Clinical
Hospital
Global Castrate Resistant Prostate Cancer Therapeutics Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Castrate Resistant Prostate Cancer Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Castrate Resistant Prostate Cancer Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Castrate Resistant Prostate Cancer Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Johnson & Johnson
Bayer AG
Dendreon Pharmaceuticals LLC
Pfizer Inc
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Castrate Resistant Prostate Cancer Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Castrate Resistant Prostate Cancer Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Castrate Resistant Prostate Cancer Therapeutics Overall Market Size
2.1 Global Castrate Resistant Prostate Cancer Therapeutics Market Size: 2022 VS 2030
2.2 Global Castrate Resistant Prostate Cancer Therapeutics Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Castrate Resistant Prostate Cancer Therapeutics Players in Global Market
3.2 Top Global Castrate Resistant Prostate Cancer Therapeutics Companies Ranked by Revenue
3.3 Global Castrate Resistant Prostate Cancer Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Castrate Resistant Prostate Cancer Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Castrate Resistant Prostate Cancer Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Castrate Resistant Prostate Cancer Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Castrate Resistant Prostate Cancer Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Castrate Resistant Prostate Cancer Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Castrate Resistant Prostate Cancer Therapeutics Market Size Markets, 2022 & 2030
4.1.2 Chemotherapy
4.1.3 Hormonal Therapy
4.1.4 Radiation Therapy
4.1.5 Other Treatment Types
4.2 By Type - Global Castrate Resistant Prostate Cancer Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Castrate Resistant Prostate Cancer Therapeutics Revenue, 2018-2023
4.2.2 By Type - Global Castrate Resistant Prostate Cancer Therapeutics Revenue, 2023-2030
4.2.3 By Type - Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Castrate Resistant Prostate Cancer Therapeutics Market Size, 2022 & 2030
5.1.2 Clinical
5.1.3 Hospital
5.2 By Application - Global Castrate Resistant Prostate Cancer Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Castrate Resistant Prostate Cancer Therapeutics Revenue, 2018-2023
5.2.2 By Application - Global Castrate Resistant Prostate Cancer Therapeutics Revenue, 2023-2030
5.2.3 By Application - Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Castrate Resistant Prostate Cancer Therapeutics Market Size, 2022 & 2030
6.2 By Region - Global Castrate Resistant Prostate Cancer Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Castrate Resistant Prostate Cancer Therapeutics Revenue, 2018-2023
6.2.2 By Region - Global Castrate Resistant Prostate Cancer Therapeutics Revenue, 2023-2030
6.2.3 By Region - Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Castrate Resistant Prostate Cancer Therapeutics Revenue, 2018-2030
6.3.2 US Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.3.3 Canada Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.3.4 Mexico Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Castrate Resistant Prostate Cancer Therapeutics Revenue, 2018-2030
6.4.2 Germany Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.4.3 France Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.4.4 U.K. Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.4.5 Italy Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.4.6 Russia Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.4.7 Nordic Countries Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.4.8 Benelux Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Castrate Resistant Prostate Cancer Therapeutics Revenue, 2018-2030
6.5.2 China Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.5.3 Japan Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.5.4 South Korea Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.5.5 Southeast Asia Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.5.6 India Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Castrate Resistant Prostate Cancer Therapeutics Revenue, 2018-2030
6.6.2 Brazil Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.6.3 Argentina Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Revenue, 2018-2030
6.7.2 Turkey Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.7.3 Israel Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.7.4 Saudi Arabia Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
6.7.5 UAE Castrate Resistant Prostate Cancer Therapeutics Market Size, 2018-2030
7 Players Profiles
7.1 Sanofi
7.1.1 Sanofi Corporate Summary
7.1.2 Sanofi Business Overview
7.1.3 Sanofi Castrate Resistant Prostate Cancer Therapeutics Major Product Offerings
7.1.4 Sanofi Castrate Resistant Prostate Cancer Therapeutics Revenue in Global Market (2018-2023)
7.1.5 Sanofi Key News
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Corporate Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Major Product Offerings
7.2.4 Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Revenue in Global Market (2018-2023)
7.2.5 Johnson & Johnson Key News
7.3 Bayer AG
7.3.1 Bayer AG Corporate Summary
7.3.2 Bayer AG Business Overview
7.3.3 Bayer AG Castrate Resistant Prostate Cancer Therapeutics Major Product Offerings
7.3.4 Bayer AG Castrate Resistant Prostate Cancer Therapeutics Revenue in Global Market (2018-2023)
7.3.5 Bayer AG Key News
7.4 Dendreon Pharmaceuticals LLC
7.4.1 Dendreon Pharmaceuticals LLC Corporate Summary
7.4.2 Dendreon Pharmaceuticals LLC Business Overview
7.4.3 Dendreon Pharmaceuticals LLC Castrate Resistant Prostate Cancer Therapeutics Major Product Offerings
7.4.4 Dendreon Pharmaceuticals LLC Castrate Resistant Prostate Cancer Therapeutics Revenue in Global Market (2018-2023)
7.4.5 Dendreon Pharmaceuticals LLC Key News
7.5 Pfizer Inc
7.5.1 Pfizer Inc Corporate Summary
7.5.2 Pfizer Inc Business Overview
7.5.3 Pfizer Inc Castrate Resistant Prostate Cancer Therapeutics Major Product Offerings
7.5.4 Pfizer Inc Castrate Resistant Prostate Cancer Therapeutics Revenue in Global Market (2018-2023)
7.5.5 Pfizer Inc Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Castrate Resistant Prostate Cancer Therapeutics Market Opportunities & Trends in Global Market
Table 2. Castrate Resistant Prostate Cancer Therapeutics Market Drivers in Global Market
Table 3. Castrate Resistant Prostate Cancer Therapeutics Market Restraints in Global Market
Table 4. Key Players of Castrate Resistant Prostate Cancer Therapeutics in Global Market
Table 5. Top Castrate Resistant Prostate Cancer Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Castrate Resistant Prostate Cancer Therapeutics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Castrate Resistant Prostate Cancer Therapeutics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Castrate Resistant Prostate Cancer Therapeutics Product Type
Table 9. List of Global Tier 1 Castrate Resistant Prostate Cancer Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Castrate Resistant Prostate Cancer Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Castrate Resistant Prostate Cancer Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Castrate Resistant Prostate Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2030
Table 14. By Application ? Global Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Castrate Resistant Prostate Cancer Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Castrate Resistant Prostate Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2030
Table 17. By Region ? Global Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Castrate Resistant Prostate Cancer Therapeutics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Castrate Resistant Prostate Cancer Therapeutics Revenue (US$, Mn), 2023-2030
Table 20. By Country - North America Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2023-2030
Table 22. By Country - Europe Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2023-2030
Table 24. By Region - Asia Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2023-2030
Table 26. By Country - South America Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2023-2030
Table 28. By Country - Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2023-2030
Table 30. Sanofi Corporate Summary
Table 31. Sanofi Castrate Resistant Prostate Cancer Therapeutics Product Offerings
Table 32. Sanofi Castrate Resistant Prostate Cancer Therapeutics Revenue (US$, Mn), (2018-2023)
Table 33. Johnson & Johnson Corporate Summary
Table 34. Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Product Offerings
Table 35. Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Revenue (US$, Mn), (2018-2023)
Table 36. Bayer AG Corporate Summary
Table 37. Bayer AG Castrate Resistant Prostate Cancer Therapeutics Product Offerings
Table 38. Bayer AG Castrate Resistant Prostate Cancer Therapeutics Revenue (US$, Mn), (2018-2023)
Table 39. Dendreon Pharmaceuticals LLC Corporate Summary
Table 40. Dendreon Pharmaceuticals LLC Castrate Resistant Prostate Cancer Therapeutics Product Offerings
Table 41. Dendreon Pharmaceuticals LLC Castrate Resistant Prostate Cancer Therapeutics Revenue (US$, Mn), (2018-2023)
Table 42. Pfizer Inc Corporate Summary
Table 43. Pfizer Inc Castrate Resistant Prostate Cancer Therapeutics Product Offerings
Table 44. Pfizer Inc Castrate Resistant Prostate Cancer Therapeutics Revenue (US$, Mn), (2018-2023)
List of Figures
Figure 1. Castrate Resistant Prostate Cancer Therapeutics Segment by Type in 2022
Figure 2. Castrate Resistant Prostate Cancer Therapeutics Segment by Application in 2022
Figure 3. Global Castrate Resistant Prostate Cancer Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Castrate Resistant Prostate Cancer Therapeutics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Castrate Resistant Prostate Cancer Therapeutics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Castrate Resistant Prostate Cancer Therapeutics Revenue in 2022
Figure 8. By Type - Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 9. By Application - Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 10. By Region - Global Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 11. By Country - North America Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 12. US Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 13. Canada Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 14. Mexico Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 15. By Country - Europe Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 16. Germany Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 17. France Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 18. U.K. Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 19. Italy Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 20. Russia Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 21. Nordic Countries Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 22. Benelux Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 23. By Region - Asia Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 24. China Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 25. Japan Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 26. South Korea Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 27. Southeast Asia Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 28. India Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 29. By Country - South America Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 30. Brazil Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 31. Argentina Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 32. By Country - Middle East & Africa Castrate Resistant Prostate Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 33. Turkey Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 34. Israel Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 35. Saudi Arabia Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 36. UAE Castrate Resistant Prostate Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 37. Sanofi Castrate Resistant Prostate Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 38. Johnson & Johnson Castrate Resistant Prostate Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 39. Bayer AG Castrate Resistant Prostate Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 40. Dendreon Pharmaceuticals LLC Castrate Resistant Prostate Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 41. Pfizer Inc Castrate Resistant Prostate Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
